Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.130
-0.190 (-5.72%)
At close: Oct 14, 2026, 4:00 PM EDT
3.129
-0.001 (-0.02%)
After-hours: Oct 14, 2026, 7:57 PM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Prime Medicine stock has a consensus rating of "Buy" and an average price target of $7.11. The average 1-year stock price forecast is 127.16% higher than the current stock price, while the lowest is $4.25 (+35.78%) and the highest is $11 (+251.44%).
Price Target: $7.11 (+127.16%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 10 | 10 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $6 | Buy | Maintains | $6 | +91.69% | Oct 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +155.59% | Oct 1, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 | Buy | Reiterates | $11 | +251.44% | Sep 25, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $9 | Buy | Maintains | $9 | +187.54% | Sep 25, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 25, 2026 |
Financial Forecast
Revenue This Year
8.83M
from 4.63M
Increased by 90.65%
Revenue Next Year
10.55M
from 8.83M
Increased by 19.47%
EPS This Year
-0.94
from -1.35
EPS Next Year
-0.89
from -0.94
EPS and Forward PE are based on non-GAAP adjusted numbers.